Core Viewpoint - Zhaoyan New Drug achieved a net profit of 0.81 billion yuan in Q1-Q3 2025, marking a turnaround to profitability, with a non-recurring net profit of 0.29 billion yuan, also indicating a return to profit [1] Financial Performance - The financial data continues to show pressure, but new signed orders exhibit a trend of marginal improvement [1] - Cumulative new signed orders for Q1-Q3 2025 amounted to approximately 16.4 billion yuan, representing a year-on-year increase of 17% [1] - New signed orders in Q3 2025 reached 6.2 billion yuan, reflecting a year-on-year growth of 24% and a quarter-on-quarter increase of 5% compared to Q2 2025 [1] Market Outlook - The order side benefits from improved client demand [1] - Considering the continuous introduction of policies encouraging innovation in China, along with the active stock prices of A+H innovative drug companies and a recovering IPO trend, domestic demand is expected to see marginal improvement in the coming years [1] - As a core participant in the domestic preclinical CRO business, the company is positioned to significantly benefit from these trends [1] Investment Rating - Adjustments have been made to previous profit forecasts based on changes in the domestic investment and financing environment and the new signed order trends from 2023 to 2025, while maintaining an "overweight" rating [1]

Investment Rating - The report maintains a "Buy" rating for the company [6]. Core Views - The financial data continues to show pressure, but new orders are showing a marginal improvement trend. The company reported a revenue of 985 million yuan for the first three quarters of 2025, a year-on-year decrease of 26.23%, but achieved a net profit attributable to shareholders of 81 million yuan, marking a return to profitability [1][2]. Financial Performance Summary - In Q3 2025, the company achieved a revenue of 316 million yuan, a year-on-year decline of 34.87%, with a gross margin of 16.32%. The overall financial data remains under pressure due to a decline in new orders in 2023-2024 [2]. - Cumulative new orders for the first three quarters of 2025 amounted to approximately 1.64 billion yuan, a year-on-year increase of 17%. In Q3 2025, new orders were 620 million yuan, up 24% year-on-year and 5% quarter-on-quarter, benefiting from improved client demand [2]. - The net profit for Q3 2025 was 20 million yuan, with the laboratory business contributing a loss of 60 million yuan, while asset management income contributed 13 million yuan. The fair value change of biological assets was 52 million yuan, indicating a decline in the net profit margin of the core laboratory service business to -18.9% due to intense competition [2]. Earnings Forecast and Investment Recommendations - Adjustments have been made to the earnings forecast for 2025-2027, with revenue estimates revised from 1.651 billion, 1.678 billion, and 1.762 billion yuan to 1.577 billion, 1.604 billion, and 1.684 billion yuan respectively. The EPS estimates were adjusted from 0.21 yuan to 0.14 yuan, 0.21 yuan to 0.15 yuan, and 0.21 yuan to 0.14 yuan for the respective years [3]. - The price-to-earnings ratio (PE) for 2025 is projected to be 230 times, 223 times for 2026, and 236 times for 2027, based on the closing price of 33.07 yuan per share on November 12, 2025 [3].

Group 1 - The core viewpoint of the news highlights the stock performance and financial metrics of Zhaoyan New Drug, indicating a 99.22% increase in stock price year-to-date, with a recent slight decline in the last five and twenty trading days [1][2] - As of September 30, 2025, Zhaoyan New Drug reported a revenue of 985 million yuan, a year-on-year decrease of 26.23%, while the net profit attributable to shareholders increased by 214.79% to 80.71 million yuan [2] - The company has a market capitalization of 24.785 billion yuan and has seen significant trading activity, with a net inflow of 1.4684 million yuan from major funds [1] Group 2 - Zhaoyan New Drug's main business involves non-clinical safety evaluation services for drugs, accounting for 95.59% of its revenue, with clinical services and experimental model supply making up the remainder [1] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed in the last three years [3] - The number of shareholders increased by 57.61% to 96,500 as of September 30, 2025, indicating growing interest in the stock [2]

Core Viewpoint - The medical services sector experienced a decline of 0.68% on November 11, with Haoyuan Pharmaceutical leading the drop. The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1]. Group 1: Market Performance - The medical services sector saw significant individual stock movements, with Yinosh rising by 10.46% to a closing price of 50.15, while Haoyuan Pharmaceutical fell by 2.95% to 75.40 [1][2]. - The trading volume for Yinosh was 33,400 hands, resulting in a transaction amount of 163 million yuan, while Haoyuan Pharmaceutical had a trading volume of 21,800 hands and a transaction amount of 166 million yuan [1][2]. Group 2: Capital Flow - The medical services sector experienced a net outflow of 746 million yuan from institutional investors, while retail investors saw a net inflow of 562 million yuan [2]. - The capital flow data indicates that Sunshine Nuohe had a net outflow of 37.39 million yuan from institutional investors, while Meidi Xi saw a net inflow of 28.62 million yuan [3].

Macroeconomic Insights - Global asset performance shows mixed results, with the Hang Seng Index up 1.29% and the Shanghai Composite Index up 1.08%, while developed markets like the S&P 500 fell by 1.63%[6] - In October, the U.S. ISM Manufacturing PMI declined, indicating economic slowdown, while consumer confidence continued to drop according to the University of Michigan index[7] Inflation and Prices - October CPI in China rose by 0.2% year-on-year, while PPI decreased by 2.1%, indicating a stable inflation environment with core service prices reaching their highest level since March 2024[11] - The rise in core CPI is attributed to reduced food drag and increased service contributions, with gold prices significantly impacting jewelry costs[13] Trade and Exports - In October, China's exports fell by 1.1% year-on-year, while imports grew by 1.0%, leading to a slight decrease in trade surplus[16] - The export structure shows weakness in non-U.S. markets, particularly the EU, while exports to the U.S. and ASEAN remained strong[18] Investment Strategies - The asset allocation report suggests an overweight position in Chinese A-shares and industrial commodities, with equity allocation set at 45% and bonds at 45%[22] - The report emphasizes the importance of AI industry trends and the potential for volatility in global equity markets, recommending a focus on quality assets[23] Market Dynamics - The trading activity has decreased, with turnover rates and transaction volumes declining across indices, indicating a cautious market sentiment[28] - The report highlights a decrease in northbound capital flow, with a net outflow of 2.6 billion CNY in the recent week, reflecting investor sentiment shifts[34]

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 39.59 CNY [5][10]. Core Insights - The company's performance is under short-term pressure, but new orders are improving, indicating potential for recovery in profitability [2][10]. - The overall order backlog as of Q1-Q3 2025 is 2.5 billion CNY, with new orders amounting to 1.64 billion CNY, reflecting a year-on-year increase of 17.1% [10]. - The company is focusing on expanding its client base, particularly large clients, with significant increases in project signings in various therapeutic areas [10]. Financial Summary - Total revenue for 2023 is projected at 2,376 million CNY, with a decline to 1,525 million CNY in 2025, representing a 24.4% decrease [3][11]. - Net profit attributable to shareholders is expected to drop significantly from 397 million CNY in 2023 to 121 million CNY in 2025, a decrease of 63.0% [3][11]. - Earnings per share (EPS) is forecasted to be 0.16 CNY in 2025, down from 0.53 CNY in 2023 [3][11]. Order Trends - The company has seen a positive trend in new orders, with Q3 2025 alone contributing approximately 620 million CNY in new contracts, a 24.0% increase year-on-year [10]. - The signing of antibody projects has increased by 20%, and projects in small nucleic acids and ADCs have seen over a 50% increase in signings [10]. Capacity and Quality Improvements - The company is steadily advancing its capacity, with new facilities in Suzhou and Guangzhou nearing completion [10]. - The company has successfully passed FDA GLP inspections, enhancing its competitive position in the industry [10].

Core Viewpoint - The futures industry is undergoing regulatory changes aimed at enhancing quality and compliance, shifting from quantity-driven growth to a focus on high-quality development and diversified services [2][4][5]. Group 1: Regulatory Changes and Industry Direction - The new regulations emphasize compliance and risk management, encouraging futures companies to create a positive industry atmosphere and enhance their service capabilities to support the real economy [2][4]. - The industry is transitioning from a marketing-oriented approach to a service-oriented model, with companies encouraged to establish compliance frameworks and improve their operational management [3][4]. Group 2: Company Strategies and Innovations - Companies like Nanhua Futures are focusing on a diversified business model that includes futures brokerage, risk management, wealth management, and overseas financial services to provide comprehensive risk management solutions [2]. - Newhu Futures is restructuring its business into four layers: intermediary, tool, trading service, and trading investment, aiming to enhance service quality and client engagement [3]. - Green Dahu Futures plans to implement a multi-faceted strategy that includes business diversification, customer diversification, and a focus on regional and functional capabilities to meet national strategic goals [4]. - Zhejiang Merchants Futures is leveraging digital innovation to improve service quality, developing platforms to address the pain points of small and medium-sized enterprises in pricing, inventory, and financing [5][6].

| 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 603127 | 說明 | | ...

Core Insights - The pharmaceutical industry is experiencing a structural change driven by the growth cycles of major products, with significant opportunities emerging in innovative drugs, medical devices, and consumer healthcare [3][6][31] - The demand for pharmaceuticals is expected to improve in 2026, supported by policies encouraging innovation and a recovery in domestic consumption [3][7] - The supply side of the pharmaceutical industry is characterized by high entry barriers due to patent protections and government regulations, which helps maintain a stable competitive environment [4][5] Group 1: Industry Trends - The aging population, urbanization, and changing disease patterns are making the pharmaceutical industry a perpetual growth sector [3] - The global pharmaceutical market has seen rapid expansion from 2009 to 2019, followed by a surge in demand due to COVID-19, and is now entering a phase of recovery and growth [3][6] - The Chinese pharmaceutical industry is expected to gradually produce world-class companies, with increasing recognition of Chinese innovative drug assets by multinational corporations (MNCs) [4][5] Group 2: Investment Opportunities - Opportunities in innovative drugs are highlighted, particularly in oncology, metabolic diseases, and autoimmune diseases, with a focus on next-generation therapies and precision medicine [6][31] - The demand for innovative drugs is expected to remain strong, with policies improving medical insurance payments and the upcoming launch of commercial insurance drug catalogs [7][31] - The medical device sector is anticipated to recover, with a focus on domestic demand and international expansion, particularly in areas with low domestic production rates [7][8] Group 3: Company Performance - Major pharmaceutical companies like Eli Lilly, AbbVie, and AstraZeneca are experiencing significant growth driven by key products, with Eli Lilly's Tirzepatide generating $24.8 billion in sales [12][15] - The report identifies specific companies such as Hengrui Medicine, Hansoh Pharmaceutical, and BeiGene as outperformers in the market, with strong pipelines and global competitiveness [7][8] - The report emphasizes the importance of mergers and acquisitions (M&A) and business development (BD) strategies for MNCs, with China becoming a significant source of projects for top global pharmaceutical companies [22][24]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分 ...